Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015', provides an overview of the Arenavirus Infection Lassa Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arenavirus Infection Lassa Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arenavirus Infection Lassa Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Arenavirus Infection Lassa Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Arenavirus Infection Lassa Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arenavirus Infection Lassa Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arenavirus Infection Lassa Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arenavirus Infection Lassa Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Arenavirus Infection Lassa Fever Overview 6
Therapeutics Development 7
Pipeline Products for Arenavirus Infection Lassa Fever - Overview 7
Pipeline Products for Arenavirus Infection Lassa Fever - Comparative Analysis 8
Arenavirus Infection Lassa Fever - Therapeutics under Development by Companies 9
Arenavirus Infection Lassa Fever - Therapeutics under Investigation by Universities/Institutes 10
Arenavirus Infection Lassa Fever - Pipeline Products Glance 11
Early Stage Products 11
Arenavirus Infection Lassa Fever - Products under Development by Companies 12
Arenavirus Infection Lassa Fever - Products under Investigation by Universities/Institutes 13
Arenavirus Infection Lassa Fever - Companies Involved in Therapeutics Development 14
Profectus BioSciences, Inc. 14
SIGA Technologies, Inc. 15
Arenavirus Infection Lassa Fever - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Molecule Type 19
Drug Profiles 21
EMER-IT - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
lassa fever vaccine - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
lassa fever vaccine 1 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
lassa fever vaccine 2 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibodies for Viral Infections - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ST-161 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ST-193 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Arenavirus Infection Lassa Fever - Recent Pipeline Updates 30
Arenavirus Infection Lassa Fever - Dormant Projects 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Number of Products under Development for Arenavirus Infection Lassa Fever, H1 2015 7
Number of Products under Development for Arenavirus Infection Lassa Fever - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Arenavirus Infection Lassa Fever - Pipeline by Profectus BioSciences, Inc., H1 2015 14
Arenavirus Infection Lassa Fever - Pipeline by SIGA Technologies, Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 17
Number of Products by Stage and Mechanism of Action, H1 2015 18
Number of Products by Stage and Molecule Type, H1 2015 20
Arenavirus Infection Lassa Fever Therapeutics - Recent Pipeline Updates, H1 2015 30
Arenavirus Infection Lassa Fever - Dormant Projects, H1 2015 31